Bispecific Antibodies: A New Era in Therapeutic Innovation

With over 600 bsAbs in clinical trials and approximately 17 approved worldwide as of early 2025, the field continues to gain momentum across oncology, immunology, and rare disease programs. Market outlooks reflect strong interest, but projections vary widely across analysts depending on scope and underlying assumptions. Some estimates place the bispecific antibody market at ~USD 12 billion in 2024 and project growth to ~USD 460 billion by 2034 under high-growth scenarios ^[1].

Building on this momentum, bsAbs are advancing into late-stage development across high-need indications, including oncology and autoimmune diseases, where dual targeting can enable differentiated therapeutic strategies. At the same time, the expanding format landscape, including bispecific antibody–drug conjugates (ADCs), raises the bar for fit-for-purpose analytical characterization and bioanalysis across development programs ^[1].

However, this therapeutic promise comes with increased molecular and functional complexity, placing greater demands on analytical characterization and bioanalysis throughout development.

Figure 1. Examples of FDA Approved BsAbs. Adapted from Klein et al., 2024 (2).

This white paper translates the therapeutic promise and analytical complexity of bispecific antibodies into decision-ready takeaways. It summarizes an orthogonal characterization toolbox and fit-for-purpose PK/TK bioanalytical strategies to support confident development and regulatory interactions.

Analytical Strategy for BsAbs

The rapid expansion of bsAb development is driving an urgent need for advanced analytical and bioanalytical strategies that can address their unique structural and functional complexity.

Due to their asymmetric architecture and dual binding sites, bsAbs are significantly more complex than conventional monoclonal antibodies. Analytical characterization must account for critical quality attributes such as proper heavy and light chain pairing, charge and glycosylation variants, aggregation, fragmentation, and other product-related impurities, each essential to ensuring product stability, purity, and efficacy [3, 4].

A robust, multi-platform analytical approach is key. Comprehensive characterization relies on a suite of orthogonal techniques, including intact and subunit mass spectrometry, peptide mapping (LC-MS/MS), size-exclusion and ion-exchange chromatography, capillary isoelectric focusing, differential scanning calorimetry, and functional assays that confirm dual binding such as Surface Plasmon Resonance or Bio-Layer Interferometry.

Table 1. Key Analytical Attributes for Post-Production Characterization of BsAbs

Abbreviations: SEC, size-exclusion chromatography; MALS, multi-angle light scattering; DLS, dynamic light scattering; nanoDSF, nano differential scanning fluorimetry; CEX, cation-exchange chromatography; cIEF, capillary isoelectric focusing.

Importantly, this characterization package is not an end in itself: it provides the evidence base to de-risk progression decisions, define meaningful specifications, and support comparability across development stages.

Once product identity and key critical quality attributes are established in vitro, the next challenge is confirming how the relevant bsAb species behave in vivo—where matrix effects, target binding, and biotransformation can materially impact PK/TK interpretation.

Bioanalysis in Complex Matrices: Measuring the Right BsAb Species in vivo

While post-production analytics are essential, in vivo bioanalysis is equally critical for successful bsAb development. Biological matrices (e.g., serum, plasma, and tissues) introduce challenges such as endogenous interferences, proteolytic degradation, and matrix-driven loss of assay specificity. Tissue bioanalysis adds an additional spatial and extraction dimension, requiring fit-for-purpose workflows that preserve bsAb integrity while minimizing matrix effects.

Conventional pharmacokinetic assays are often insufficient for bsAbs because these molecules can exist as multiple circulating species (e.g., intact bispecific, monospecific or mispaired variants, and target-bound complexes). This becomes particularly relevant when the target is soluble or shed: binding in circulation can alter distribution and clearance and may mask detection depending on assay design. In such cases, quantifying both free (pharmacologically available) and total (free plus bound) bsAb can be critical to interpret exposure, pharmacodynamics, and safety with confidence.

To fully characterize bsAb behavior in vivo, bioanalytical strategies should therefore extend beyond total concentration and, where appropriate, capture functionally relevant species and binding-domain activity (separately and/or in combination). This evidence base supports more informed decision-making and reduces regulatory risk across complex development pathways.

Selecting the right assay format is essential for generating meaningful bioanalytical data in bsAb development. While ligand-binding assays (LBAs) remain a gold standard due to their sensitivity and scalability, their performance depends heavily on the availability of highly specific reagents. In particular, access to high-quality target antigens and anti-idiotypic antibodies is critical for robust method design, selectivity in complex matrices, and reliable quantification.

As the molecular diversity of bsAbs continues to expand, immunoaffinity-LC-MS (IA-LC-MS) is increasingly valuable. By combining selective immunocapture with enhanced resolution of mass spectrometry, it enables quantification of surrogate peptides representing each binding arm and detects subtle structural changes or biotransformation. This makes it a powerful tool for structural and functional characterization in PK/TK studies.

Table 2. Comparison of Bioanalytical Approaches for BsAb PK Characterization

Every bioanalytical approach brings distinct strengths and trade-offs. LBAs remain the benchmark for sensitivity and scalability, but performance is ultimately constrained by reagent availability and selectivity in complex matrices. IA-LC-MS provides complementary capabilities, offering enhanced structural resolution and improved differentiation of relevant bsAb species when heterogeneity or biotransformation becomes a concern.

The key is not choosing one over the other, but developing the assay best aligned with your study objectives. By tailoring the strategy to your program’s unique challenges, you ensure meaningful, reliable insights that drive confident decision-making and accelerate bsAb development.

Building Analytical Confidence in BsAbs

Bispecific antibodies combine strong therapeutic potential with elevated analytical and bioanalytical complexity.
A lifecycle-minded, fit-for-purpose strategy, built on orthogonal characterization and decision-relevant bioanalysis, enables interpretable data, reduces risk, and supports confident development and regulatory interactions. In practice, an integrated analytical and bioanalytical strategy becomes a competitive advantage – one that Conscio Group supports through end-to-end assay strategy, development, and implementation aligned to program objectives and regulatory expectations.

Sources

1. Towards Healthcare. Bispecific Antibody Market Size, Share, Trends, & Forecast 2024–2034. Retrieved October 2025, from https://www.towardshealthcare.com/insights/bispecific-antibody-market-sizing.
2. Klein, C., et al. The present and future of bispecific antibodies for cancer therapy. Nature reviews Drug discovery, 2024.
3. Xu, Y., et al. A systematic approach for analysis and characterization of mispairing in asymmetric bispecific antibodies. mAbs, 2018. PMC6284573.
4. Duivelshof, B. L., et al. Bispecific antibody characterization by LC/MS techniques. Analytical Biochemistry, 2021.
5. Agilent Technologies. Overcoming the Challenges of Bispecific Antibody Characterization Using New Column Chemistries to Detect Product Impurities. ASMS 2021 Poster. Available at: ASMS Poster PDF
6. Evans, A. R., et al. Using bispecific antibodies in forced degradation studies. mAbs, 2019. Taylor & Francis.
7. Agilent Technologies. Detailed Aggregation Characterization of Monoclonal Antibodies Using the Agilent 1260 Infinity Multi-Detector Bio-SEC Solution. Application Note. Agilent PDF 5991-3954EN.
8. Agilent 1260 Infinity Multi-Detector Bio-SEC Solution with Advanced Light Scattering Detection. Application Note. Agilent PDF 5991-5220EN.
9. Agilent Technologies. Surmounting the Challenges of Bispecific Antibody Characterization. Application Note. Agilent PDF 5991-5220EN.
10. General charge variant analyses and workflows for bispecific antibodies (e.g., literature, vendor notes).
11. Cheng, F., et al. Detailed Analytical Characterization of a Bispecific IgG1 CrossMab. 2022. PMC8811765.
12. Craft, J., et al. Integrated immunogenicity risk assessment of bispecific antibodies. mAbs, 2021. PMC8265794.
13. Zhang, J., et al. Characterization of Bispecific Antibody Production in Cell Cultures by LC-MS. Analytical Chemistry, 2020.
14. ICH M10: Bioanalytical Method Validation (2022); FDA Bioanalytical Method Validation Guidance (2018).
15. Van den Broek I. et al. Immunocapture coupled with LC–MS: New paradigms in bioanalysis. Bioanalysis. 2021.
16. Gstöttner C. et al. Intact and subunit-specific analysis of bispecific antibodies by sheathless CE-MS. Anal Chem. 2020.
17. Hörner S. et al. Mass spectrometry for quality control of bispecific antibodies after SDS‐PAGE in‐gel digestion. Biotechnol Bioeng. 2021.
18. Nowatzke W. et al. Quantification of Free and Total Therapeutic mAbs by Hybrid Ligand-Binding Assay-LC–MS/MS. Bioanalysis. 2022.

Would you like to know more? Contact our team.